Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

NeuroFerro Ferroptosis Inhibitors For Neurodegenerative Disorders

Coordinator
Universiteit Antwerpen, Belgium
Runs
1 October 2022 to 31 March 2025
Status
Running
EU funding
€240k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101065370

What the project is doing

In the project's own words, from its summary on CORDIS.

FERROptosis inhibitors for NEUROdegenerative disorders (NeuroFerro) will focus on the development of potent compounds with improved pharmacokinetic properties, including blood-brain barrier (BBB) permeability for future application in the treatment of neurodegenerative disorders. Ferroptosis is non-apoptotic programmed cell death that has been linked to the pathophysiological processes of many diseases, including dementia, Huntingtons disease, Alzheimers disease, Parkinsons disease and amyotrophic lateral sclerosis (ALS).

Neurological disorders are one of the most significant causes of disability-adjusted life-years and death worldwide with very limited treatment available. Although ferroptosis inhibitors developed by Augustyns and Vanden Berghe (supervisors) are currently best in class compounds, they suffer from no or minor BBB permeability. Therefore the main aim of the project will be the design and synthesis of novel ferroptosis inhibitors with improved pharmacokinetic parameters and high blood-brain barrier permeability to target ferroptosis in neurodegenerative disorders.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit AntwerpenAntwerpenBelgiumCoordinator
Ryvu Therapeutics S.A.KrakówPolandAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI